AstraZeneca to Buy Biotech Amolyt for $1.5 Billion
- March 15, 2024
AstraZeneca plc plans to acquire French biotechnology firm Amolyt Pharma, which focuses on developing treatments for rare endocrine diseases, in a deal valued at up to $1.5 billion, according to a March 14 announcement.
ARTICLE TAGS
You must be logged in to access this content.